CABi001-A, PRPF31-MiPS4F3
ESi077-A
General
Cell Line |
|
| hPSCreg Name | ESi077-A |
| Alternative name(s) |
CABi001-A, PRPF31-MiPS4F3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 19th September 2020 |
| User feedback | |
Provider |
|
| Generator | Spanish Stem Cell Bank (ES) |
External Databases |
|
| Cellosaurus | CVCL_UJ71 |
| BioSamples | SAMEA7484330 |
| CLO | CLO_0103058 |
| Wikidata | Q93545418 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| All cell lines of this donor's relatives |
Has son:
|
External Databases (Donor) |
|
| BioSamples | SAMEA7484331 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | berta.delacerda@cabimer.es |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Comité Coordinador de Ética de a Investigación Biomédica de Andalucía |
| Approval number | PR-01-2015 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Comité Coordinador de Ética de a Investigación Biomédica de Andalucía |
| Approval number | PR-01-2015 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Derived Peripheral Blood Mononuclear CellMononuclear cells collected from peripheral blood.
Synonyms
|
| Source cell origin |
BloodA liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | rtPCR to detect ectopic reprogramming factors and capsid gene. c+ is PRPF31-MiPS4F3 at passage 1 and c- is a primary cell sample (PBMCs). Third lane shows the silencing of the virus in the PRPF31-MiPS4F3 line at passage 6 |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Manually picking iPS clones with ESC-morphology and positive for in vivo TRA-1-60 immunofluorescent staining. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Dispase
|
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| SSEA-3 |
Yes |
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Passage number: 13
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.